Ownership and insider activity for IDEAYA Biosciences, Inc. (IDYA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs.
Price
| Price | $37.73 |
| Market Cap | $3.6B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.0M | $20.5M | $34.1M | $72.0M | $92.0M | $68.6M | $157.0M | $84.4M | $112.8M |
| Short-term Investments | $7.2M | $69.5M | $64.9M | $211.5M | $154.7M | $296.2M | $368.1M | $591.9M | $526.6M |
| Receivables | 0 | 0 | 0 | $1.9M | $1.1M | $211000 | $18000 | $3000 | $6.0M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $13.6M | $90.7M | $101.7M | $288.6M | $251.0M | $370.5M | $532.6M | $689.7M | $666.7M |
| Property, Plant & Equipment | $3.7M | $5.2M | $9.7M | $9.5M | $8.7M | $9.0M | $8.4M | $27.7M | $31.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $17.5M | $96.5M | $113.0M | $298.3M | $381.3M | $388.0M | $649.3M | $1.12B | $1.11B |
| Accounts Payable | $662000 | $1.4M | $709000 | $953000 | $2.1M | $4.3M | $6.6M | $15.4M | $17.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $339000 |
| Total Current Liabilities | $2.4M | $5.4M | $6.9M | $38.6M | $45.2M | $31.7M | $27.1M | $46.1M | $58.8M |
| Long-term Debt | $3.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $27.6M |
| Total Liabilities | $33.2M | $145.5M | $12.6M | $100.0M | $79.8M | $38.5M | $28.2M | $64.9M | $86.4M |
| Retained Earnings | -$16.2M | -$50.5M | -$92.5M | -$127.0M | -$176.7M | -$235.4M | -$348.4M | -$622.8M | -$736.5M |
| Total Equity | -$15.7M | -$48.9M | $100.4M | $198.3M | $301.5M | $349.5M | $621.1M | $1.06B | $1.02B |
| Total Debt | $3.2M | 0 | $6.8M | $6.7M | $5.2M | $3.5M | $2.9M | $19.2M | $27.9M |
| Net Debt | -$9.9M | -$90.0M | -$92.2M | -$276.9M | -$241.6M | -$361.3M | -$522.2M | -$657.1M | -$611.5M |
| Working Capital | $11.1M | $85.3M | $94.7M | $250.0M | $205.8M | $338.7M | $505.5M | $643.6M | $607.9M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 10.45 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 20.70 |
Profitability
| Return on Equity | -16.47% |
| Return on Invested Capital | -17.66% |
| Return on Assets | -13.36% |
| Gross Margin | -13.32% |
| Operating Margin | -92.66% |
| Net Margin | -74.75% |
Related companies: ADPT · BEAM · CDTX · COGT · FOLD · KNSA · LEGN
Explore sector: Healthcare · Biotechnology
More sections of IDYA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks